irbesartan + placebo
ApprovedUNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Persistent Atrial Fibrillation
Conditions
Persistent Atrial Fibrillation
Trial Timeline
May 1, 2009 → May 1, 2010
NCT ID
NCT00613496About irbesartan + placebo
irbesartan + placebo is a approved stage product being developed by Sanofi for Persistent Atrial Fibrillation. The current trial status is unknown. This product is registered under clinical trial identifier NCT00613496. Target conditions include Persistent Atrial Fibrillation.
What happened to similar drugs?
3 of 7 similar drugs in Persistent Atrial Fibrillation were approved
Approved (3) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00613496 | Approved | UNKNOWN |
| NCT00265642 | Phase 3 | Completed |
Competing Products
20 competing products in Persistent Atrial Fibrillation